Mexco Energy Corporation (MXC)

NYSE American - NYSE American Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

17.98

-0.02

(-0.11%)

At close: 03:59PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	18.86
Open	20.00
Bid	14.46 x 900
Ask	18.30 x 2900
Day's Range	18.00 - 20.00
52 Week Range	7.80 - 43.00
Volume	13,858
Avg. Volume	26,941

Market Cap	38.148M
Beta (5Y Monthly)	1.26
PE Ratio (TTM)	23.38
EPS (TTM)	0.77
Earnings Date	Feb 08, 2022 - Feb 14, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

All

GlobeNewswire
Mexco Energy Corporation Reports Financial Results for First Quarter
MIDLAND, TX, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $1,298,672, or $0.59 per diluted share, for the quarter ending June 30, 2022, the Company’s first quarter of fiscal 2023, an increase of 340% versus $395,006 or $0.19 per diluted share, for the comparable quarter ending June 30, 2021. Operating revenues in the first quarter of fiscal 2023 increased 94% to $2,449,973 from $1,264,198 for the first quarter of fiscal 2022. This i
- ProAssurance (PRA) Jumps 7.1% Since Q2 Earnings Beat Estimates
  Zacks
- Pembina (PBA) Stock Rises 2% After Q2 Earnings Beat Estimates
  Zacks
GlobeNewswire
MEXCO ENERGY CORPORATION REPORTS FINANCIAL RESULTS FOR FISCAL 2022
MIDLAND, TX, June 27, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2022. The Company reported net income of $2,855,066 or $1.36 per diluted share, for fiscal year 2022, compared to net income of $155,932, or $0.08 per diluted share, for fiscal 2021. Operating revenues in fiscal 2022 were $6,587,780, an increase of 135% when compared to fiscal 20
PR Newswire
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK
MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.